Sukumar Nagendran insider trades: Taysha Gene Therapies (TSHA) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Sukumar reports to the SEC
Open-market buys and sales
21 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jul 10, 2026 | TSHA | ↓ Sell | 200,000 | $6.24 | $1.2M | Direct | Jul 10, 2026 (0d) |
| Apr 10, 2026 | TSHA | ↓ Sell | 200,000 | $4.46 | $892K | Direct | Apr 13, 2026 (3d) |
| Jan 26, 2026 | TSHA | ↓ Sell | 116,050 | $4.72 | $547K | Direct | Jan 27, 2026 (1d) |
| Jan 12, 2026 | TSHA | ↓ Sell | 200,000 | $4.71 | $942K | Direct | Jan 14, 2026 (2d) |
| Dec 1, 2025 | TSHA | ↓ Sell | 370,172 | $4.58 | $1.7M | Direct | Dec 1, 2025 (0d) |
| Sep 10, 2025 | TSHA | ↓ Sell | 200,000 | $3.23 | $646K | Direct | Sep 12, 2025 (2d) |
| Aug 21, 2025 | TSHA | ↓ Sell | 57,054 | $2.85 | $163K | Direct | Aug 22, 2025 (1d) |
| May 16, 2023 | TSHA | ↑ Buy | 5,000 | $0.68 | $3K | Direct | May 18, 2023 (2d) |
| Feb 2, 2022 | TSHA | ↑ Buy | 10,000 | $8.01 | $80K | Direct | Feb 3, 2022 (1d) |
| Mar 1, 2018 | AVXS | ↓ Sell | 1,780 | $126.19 | $225K | Direct | Mar 5, 2018 (4d) |
| Feb 1, 2018 | AVXS | ↓ Sell | 1,780 | $117.96 | $210K | Direct | Feb 5, 2018 (4d) |
| Jan 2, 2018 | AVXS | ↓ Sell | 1,780 | $109.72 | $195K | Direct | Jan 4, 2018 (2d) |
| Dec 1, 2017 | AVXS | ↓ Sell | 1,780 | $94.77 | $169K | Direct | Dec 5, 2017 (4d) |
| Nov 1, 2017 | AVXS | ↓ Sell | 1,780 | $101.26 | $180K | Direct | Nov 3, 2017 (2d) |
| Oct 2, 2017 | AVXS | ↓ Sell | 1,780 | $97.25 | $173K | Direct | Oct 3, 2017 (1d) |
| Sep 1, 2017 | AVXS | ↓ Sell | 1,780 | $93.25 | $166K | Direct | Sep 5, 2017 (4d) |
| Aug 1, 2017 | AVXS | ↓ Sell | 1,780 | $91.52 | $163K | Direct | Aug 3, 2017 (2d) |
| Jul 3, 2017 | AVXS | ↓ Sell | 1,780 | $81.88 | $146K | Direct | Jul 5, 2017 (2d) |
| Jun 1, 2017 | AVXS | ↓ Sell | 1,780 | $70.91 | $126K | Direct | Jun 2, 2017 (1d) |
| May 1, 2017 | AVXS | ↓ Sell | 1,780 | $81.39 | $145K | Direct | May 2, 2017 (1d) |
| Apr 3, 2017 | AVXS | ↓ Sell | 1,781 | $76.13 | $136K | Direct | Apr 5, 2017 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other TSHA insiders
Open-market trades in the last 12 months
About Sukumar Nagendran's insider trades
Sukumar Nagendran is President and Head of R&D at Taysha Gene Therapies (TSHA). Since Apr 3, 2017, Sukumar has reported 2 open-market purchases worth $84K and 19 sales worth $8.2M on SEC Form 4. In the last 12 months: 5 sales ($5.3M).
Their filings also include grants and awards (24 filings), option exercises (16 filings), conversions (1 filing), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TSHA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.